Hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance.
about
Vascular endothelial dysfunction and pharmacological treatmentStatins in Asthma: Potential Beneficial Effects and LimitationsNitric oxide synthases: regulation and functionEffect of lovastatin on coxsackievirus B3 infection in human endothelial cellsDefects in caveolin-1 cause dilated cardiomyopathy and pulmonary hypertension in knockout miceSubmaximal exercise coronary artery flow increases in postmenopausal women without coronary artery disease after estrogen and atorvastatin.Statins and cardiovascular diseases: from cholesterol lowering to pleiotropyCaveolae create local signalling domains through their distinct protein content, lipid profile and morphologyCaveolin contributes to the modulation of basal and β-adrenoceptor stimulated function of the adult rat ventricular myocyte by simvastatin: a novel pleiotropic effectOxidative stress markers are associated to vascular recurrence in non-cardioembolic stroke patients non-treated with statins.Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.Simvastatin prevents inflammation-induced aortic stiffening and endothelial dysfunction.The anti-ischemic and anti-anginal properties of statinsGlial-neuronal-endothelial interactions are involved in the control of GnRH secretion.Antiarrhythmic effects of simvastatin in canine pulmonary vein sleeve preparationsRepression of BK virus infection of human renal proximal tubular epithelial cells by pravastatin.Microcirculation as a target for the anti-inflammatory properties of statins.Modulation of cardiac contraction, relaxation and rate by the endothelial nitric oxide synthase (eNOS): lessons from genetically modified mice.How to grow bone to treat osteoporosis and mend fractures.Beyond lipid-lowering: effects of statins on endothelial nitric oxide.Prospects of statins in Parkinson diseaseImpact of olmesartan on blood pressure, endothelial function, and cardiovascular outcomes.Therapeutic effect of enhancing endothelial nitric oxide synthase (eNOS) expression and preventing eNOS uncoupling.Myocardial infarction in young adults.Short-term effect of atorvastatin on carotid artery elasticity: a pilot studyShort-term statin treatment improves endothelial function and neurohormonal imbalance in normocholesterolaemic patients with non-ischaemic heart failure.Microvascular responsiveness in obesity: implications for therapeutic intervention.Impact of HMG-CoA reductase inhibitors on the incidence of polyomavirus-associated nephropathy in renal transplant recipients with human BK polyomavirus viremiaLipid-lowering drugs.Pleiotropic effects of statins: moving beyond cholesterol control.Fibrinogen/LDL apheresis is a promising rescue therapy for sudden sensorineural hearing loss.Future prospects of anticytokine therapy in chronic heart failure.Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials.Modulation by simvastatin of iberiotoxin-sensitive, Ca2+-activated K+ channels of porcine coronary artery smooth muscle cells.Endothelial dysfunction links erectile dysfunction to heart disease.Evidence for statin therapy in polycystic ovary syndrome.Should all diabetic patients receive statins?Diabetes mellitus-associated atherosclerosis: mechanisms involved and potential for pharmacological invention.The effects of HMG-CoA reductase inhibitors on endothelial function.Recent advances in understanding endothelial dysfunction in atherosclerosis.
P2860
Q26774561-CB89D459-40D9-49C6-B318-270E20F7F76EQ26776067-0EF30697-516D-45A4-85A7-D8DEB0CD7D37Q28247092-E597D1DE-1BE4-4804-879B-0AE172CDA8C2Q28303547-A8B3D9CE-F683-443D-8AE5-76C503FD761AQ28508575-E1CC5A56-EB9E-4A71-AE70-7594BAF2DFC7Q33590651-01BAC3C6-414E-4BB9-A03B-1E0039880E33Q33960556-79896EC5-B1BE-4C69-987D-02CE49A0CBC6Q33998121-482CFE5B-541A-4921-84BB-DA4614F9D7F2Q34166022-B7EA200B-1BF2-4784-BEDE-81D7EE2AC9D2Q34365602-426611F7-67AC-4788-9AD8-120FB39E1011Q34427770-636447F3-7B2E-443F-BD35-330D2467FEC0Q34457410-72A09362-81A3-41F3-834A-0F9D9F8A1B6AQ34477330-F068D3BA-E2E5-4B82-B1BE-633B86FD31EAQ34630869-05DCD800-5DEE-401F-A551-3C21E7BC4BD7Q34682939-2E230C81-EB97-4B38-B9ED-016DA16486D1Q34778299-26A4F82E-19F4-4425-971D-2ADD8DA4897BQ35026501-A8A3649D-B6F8-4061-97FF-8A24155B4F4CQ35037549-7D3D5861-46FE-4B71-8956-A8342939E93AQ35067951-0671C83F-4D22-4783-B76F-548BDFF458D8Q35084723-2066FE93-CE09-4883-AE13-3E8E46831F73Q35094028-72387648-F426-46E1-8E1A-B8F3731DBB6AQ35210513-FAAC497B-4A10-4E8D-9ACD-241A1DBB52A7Q35216447-FF9A2285-7238-4221-B59D-4C065C2A823CQ35523257-09D5B54B-7278-4434-A4FD-57C4DA4D8CCAQ35581183-4949385D-925E-496A-921F-C5F2CDE1FA86Q35772664-F2D06FAD-A6F2-4268-A4B9-33A4D2E64791Q35859728-84AB6E7D-61B7-4001-BA6B-FF6EEAA07AE2Q35930371-AF7DB053-F60E-4FE6-A6CF-8C8F64867E89Q36002780-8AC45AF1-22D0-405F-80D3-EEE9633833CEQ36025981-93D66C80-4178-437B-AA15-FC223578248EQ36028599-021B7A32-5988-4767-A2FF-F4DE68514994Q36087238-6154B3E2-731A-4643-AABA-CF350C04F73BQ36088110-60E62AC9-D51F-46FC-B83B-1B72370C4FE5Q36094290-2D7E19D0-B1FC-46C9-A18F-5665B552E69BQ36107919-1FF885DC-A525-435C-8559-4F4B2E6F0E03Q36327934-C6C295E7-EFDA-478C-9828-44D5FCC682B3Q36385133-4BF8B320-FA47-4880-9E46-36D77CE5C5EBQ36401585-65381EC9-E154-4B02-BB6E-6AC2FEE2C62DQ36429347-8B6A539F-01EC-44E0-90CA-DC6ABBB91452Q36440894-D4D53576-4BFD-48BD-A0DC-44646DDA4AAC
P2860
Hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Hydroxy-methylglutaryl-coenzym ...... ecrease in caveolin abundance.
@ast
Hydroxy-methylglutaryl-coenzym ...... ecrease in caveolin abundance.
@en
type
label
Hydroxy-methylglutaryl-coenzym ...... ecrease in caveolin abundance.
@ast
Hydroxy-methylglutaryl-coenzym ...... ecrease in caveolin abundance.
@en
prefLabel
Hydroxy-methylglutaryl-coenzym ...... ecrease in caveolin abundance.
@ast
Hydroxy-methylglutaryl-coenzym ...... ecrease in caveolin abundance.
@en
P2093
P356
P1433
P1476
Hydroxy-methylglutaryl-coenzym ...... ecrease in caveolin abundance.
@en
P2093
P304
P356
10.1161/01.CIR.103.1.113
P407
P577
2001-01-01T00:00:00Z